Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunnigan's Partial Familial Lipodystrophy by Replacing 75 g of Glucose With a Standardized Carbohydrate Breakfast and Continuous Interstitial Monitoring Glucose)
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LA RÉUNION · Mar 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to diagnose diabetes and prediabetes in patients with a rare condition called Dunnigan's partial familial lipodystrophy. This condition affects how fat is distributed in the body, leading to insulin resistance and a higher risk of diabetes. Traditionally, doctors use a test called the Oral Glucose Tolerance Test (OGTT) to check for diabetes, but many patients find this test uncomfortable. To make it easier, this study is exploring whether having a standardized breakfast that contains the same amount of carbohydrates as the OGTT can give similar results. Additionally, the trial will use a continuous glucose monitor to track blood sugar levels over several days, which may help detect problems that a single test might miss.
To participate in this trial, you must be between 18 and 75 years old, have Dunnigan's lipodystrophy, and not be diabetic. You'll need to provide your consent to join the study. If you take part, you'll consume a special breakfast and wear a glucose monitor for several days. This could provide valuable information to help manage your health. It's important to know that this study is currently recruiting participants, and you're invited to ask questions if you're interested.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject with Dunnigan's partial familial lipodystrophy followed at Reunion University Hospital not known to be diabetic.
- • Aged 18 to 75 Having given their informed consent.
- Exclusion Criteria:
- • Diabetic patient Patient scheduled for scan within 7 days of freestyle placement protected persons: "pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, minor, and person subject to a measure of legal protection: guardianship or curatorship)"
About Centre Hospitalier Universitaire De La Réunion
The Centre Hospitalier Universitaire de la Réunion (CHU Réunion) is a leading academic medical center located on the island of Réunion. As a prominent clinical trial sponsor, CHU Réunion is dedicated to advancing medical research and improving patient care through innovative therapeutic studies and collaborations. With a focus on multidisciplinary approaches, the institution leverages its expertise in various medical fields to address pressing health challenges, enhance clinical practices, and promote evidence-based medicine. CHU Réunion is committed to ensuring patient safety and ethical standards in all research endeavors, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Denis, , Réunion
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials